Natera, Inc. (NASDAQ:NTRA) will be releasing its Q3 2017 earnings data after the market closes on Tuesday, November 7th. Analysts expect Natera to post earnings of ($0.47) per share for the quarter.
Natera (NASDAQ:NTRA) last posted its earnings results on Tuesday, August 8th. The medical research company reported ($0.52) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.52). Natera had a negative return on equity of 137.46% and a negative net margin of 62.64%. The company had revenue of $53.60 million during the quarter, compared to analyst estimates of $50.57 million. During the same period in the previous year, the company earned ($0.46) EPS. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. On average, analysts expect Natera to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Natera, Inc. (NASDAQ:NTRA) opened at $10.88 on Friday.
COPYRIGHT VIOLATION WARNING: This article was posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.com-unik.info/2017/11/05/natera-inc-ntra-set-to-announce-earnings-on-tuesday.html.
In other Natera news, insider Jonathan Sheena sold 120,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $12.54, for a total value of $1,504,800.00. Following the sale, the insider now owns 533,208 shares in the company, valued at approximately $6,686,428.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 12.57% of the company’s stock.
Several brokerages recently issued reports on NTRA. ValuEngine lowered Natera from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. Cowen and Company reiterated a “buy” rating and issued a $14.00 price objective on shares of Natera in a research report on Friday, September 1st. Robert W. Baird reiterated a “buy” rating on shares of Natera in a research report on Tuesday, October 24th. Zacks Investment Research lowered Natera from a “buy” rating to a “sell” rating in a research report on Saturday, August 12th. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $16.00 price objective (up from $13.00) on shares of Natera in a research report on Friday, October 6th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. Natera presently has an average rating of “Buy” and a consensus price target of $16.20.
What are top analysts saying about Natera Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Natera Inc. and related companies.